Alphatec Holdings, Inc. - Common Stock (ATEC)

Specializing in spinal surgery devices, this medical technology firm reported a notable insider sale amid strong 12-month share price gains.

ATEC stock shows strong technicals and a high-quality price pattern, signaling a potential breakout from its current pause in a clear uptrend.

This U.S. spinal surgery innovator reported insider selling amid a year of strong share price gains and ongoing direct-to-surgeon growth.

An HR executive at Alphatec sold 7.2% of his stake in the company for $2 million.

Harrow’s accelerating revenue and expanding product portfolio may help explain why a fundamentals-focused investment firm just made it a new position.

One small-cap specialist just made a surprisingly large bet on one of telecom’s most complicated turnarounds.

This private-equity-style shop trimmed its position in a financial technology firm that's posting record numbers despite a steep stock decline.

Alphatec Holdings (ATEC) fits Mark Minervini's Trend Template, showing a strong technical uptrend and high-growth fundamentals with accelerating revenue.

Before the US market kicks off on Friday, let's examine the pre-market session and unveil the notable performers among the top gainers and losers.

The regular session of the US market on Thursday is now over, but let's get a preview of the after-hours session and explore the top gainers and losers driving the post-market movements.

Alphatec Holdings (ATEC) smashed Q3 2025 earnings estimates, beating on revenue and swinging to a profit. The stock surged over 21% as the company also raised its full-year 2025 guidance.

The pharmaceutical landscape is currently a tale of two giants employing vastly different, yet highly successful, growth strategies. Eli Lilly and Company (NYSE: LLY) has placed an extraordinary bet on the burgeoning market for weight-loss and diabetes drugs, driven by its groundbreaking GLP-1 agonists. In stark contrast, Johnson & Johnson (NYSE:

ATEC stock excels in both technical momentum and fundamental growth, meeting Mark Minervini's strict Trend Template criteria for high-growth investors.

Carlsmed secures NTAP reimbursement and FDA support, while BofA projects strong revenue growth and assigns a Buy rating with a $16 target.